Category Medicine and Healthcare
Press Release
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 Read More
Press Release
ZetrOZ Systems’ Sustained Acoustic Medicine Helps with Costly Injuries to Military Personnel
Nearly half of all active-duty Army personnel suffer injuries that sideline them for weeks of service to the country and cost the U.S. billions of dollars. The sam® wearable ultrasound unit can help military personnel return to service by speeding soft tissue healing. Read More
Press Release
Neurocare Group Receives FDA Clearance for Its Industry-Leading Intermittent Theta Burst Stimulation (iTBS) Protocol for Transcranial Magnetic Stimulation (TMS)
neurocare is pleased to announce that it has received FDA clearance for its industry-leading intermittent Theta Burst Stimulation (iTBS) protocol, available across its Apollo TMS Therapy System and other Transcranial Magnetic Stimulation systems for clinical practice. Read More
Press Release
MMJ Biopharma Cultivation Exposes Biden Harris DEA Administrator's Hypocrisy
Milgram's public statements, juxtaposed with the DEA's restrictive actions, paint a picture of an agency at odds with itself-one that claims to prioritize public health while simultaneously obstructing access to innovative treatments that could save lives. As the legal and public pressure mounts, the DEA may be forced to reconsider its approach, leading to a new era of drug policy in America Read More
Press Release
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications Read More
Press Release
Iodine Software Unveils New Innovation for Its AwareUM Software to Support Third-Party Physician Advisors (PAs) and Drive Improved Efficiencies With a Superior Customer Experience
AwareUM's unified and closed-loop review workflow is critical to maximize team productivity and enhance stakeholder communication and collaboration Read More
Press Release
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 Read More
Press Release
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi™ and FDA Accepts Biosimilar Biologics License Application for TX-05
FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex's Expertise in Biologics Development and Manufacturing. Read More
Press Release
Dr. Paul Vitenas Named on Texas Super Doctors® for 2024 in Texas Monthly's 21st Year Celebration
Celebrated for His Expertise in Breast Augmentation, Facial Rejuvenation and Body Contouring, Dr. Vitenas Continues to Lead in Patient Care, Earning Recognition on the Texas Super Doctors® List for 2024 Read More
Press Release
OS Therapies Reports Second Quarter 2024 Financial Results
Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all reported outstanding preferred shares and debt into equity occurred as of the date of the IPO and is not reflected in the reported financials After IPO and preferred shares and debt conversion share issuances, there are 20.85 million common shares outstanding, with 1.86 million common shares available to be traded Underwriter lockups limit potential for deposit or trading of remaining 18.99 million common shares As of the date of the IPO, Company had no debt, cash runway for lead program OST-HER2 into mid-2025 Read More
Press Release
Interactive Strength Inc. (Nasdaq: TRNR) Reports Second Quarter 2024 Results
Net Loss and Earnings per Diluted Share of $10.6 million and $17.48 Adjusted EBITDA was a $2.9 million loss, a $2.8 million improvement versus second quarter of 2023 The Company expects to generate between $2.0 million and $2.5 million in revenue in the third quarter of 2024 Read More
Press Release
Monogram Technologies Reports Second Quarter 2024 Financial Results
Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time Read More
Press Release